Hana Pharm Co Ltd
Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally. It offers anesthetics, narcotic analgesics, antiemetics, muscle relaxants, cardiovascular and endocrine system, gastrointestinal system, respiratory system, antibiotics, dermatology, urinology, osteoporosis, and central nervous system products, as well as analgesics, antipyretics, and an… Read more
Hana Pharm Co Ltd (293480) - Total Liabilities
Latest total liabilities as of September 2025: ₩98.98 Billion KRW
Based on the latest financial reports, Hana Pharm Co Ltd (293480) has total liabilities worth ₩98.98 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hana Pharm Co Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Hana Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hana Pharm Co Ltd Competitors by Total Liabilities
The table below lists competitors of Hana Pharm Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LGL Group Inc
NYSE MKT:LGL
|
USA | $1.38 Million |
|
Pan Brothers Tbk
JK:PBRX
|
Indonesia | Rp130.50 Million |
|
SFOODS
HE:SFOODS
|
Finland | €20.90 Million |
|
LivePerson Inc
NASDAQ:LPSN
|
USA | $512.84 Million |
|
Argo Group International Holdings Ltd
OTCQX:ARGHF
|
USA | $23.27 Million |
|
Arrienda Rental Properties SOCIMI SA
MC:YARP
|
Spain | €22.09 Million |
|
Hudson Acquisition I Corp. Common Stock
NASDAQ:HUDA
|
USA | $7.47 Million |
|
Trident Digital Tech Holdings Ltd American Depository Shares
NASDAQ:TDTH
|
USA | $6.43 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Hana Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hana Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hana Pharm Co Ltd (2016–2024)
The table below shows the annual total liabilities of Hana Pharm Co Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩72.83 Billion | +3.46% |
| 2023-12-31 | ₩70.40 Billion | -9.24% |
| 2022-12-31 | ₩77.57 Billion | +50.34% |
| 2021-12-31 | ₩51.60 Billion | +16.74% |
| 2020-12-31 | ₩44.20 Billion | +3.50% |
| 2019-12-31 | ₩42.70 Billion | +15.43% |
| 2018-12-31 | ₩36.99 Billion | -38.60% |
| 2017-12-31 | ₩60.25 Billion | +1.94% |
| 2016-12-31 | ₩59.11 Billion | -- |